Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Benson Edagwa Clear advanced filters

  • Antiretroviral therapy (ART) for the treatment of HIV-1 requires life-long daily adherence to supress viral replication, and nucleoside reverse transcriptase inhibitors that are commonly used in ART have not been converted into long-acting agents. Here, the authors report two lipophilic tenofovir (TVF) ProTide nanoformulations, NM1TFV and NM2TFV, which sustain drug levels above therapeutic concentrations for two months after a single intramuscular dose in rats.

    • Denise A. Cobb
    • Nathan Smith
    • Benson Edagwa
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-16

  • Here, using animal models, Deodhar et al. single parenteral dose of dolutegravir (DTG) prodrug nanocrystals sustains drug protein-adjusted 90% inhibitory concentration for up to a year, without injection site reactions or systemic toxicities.

    • Suyash Deodhar
    • Brady Sillman
    • Howard E. Gendelman
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-15

  • Nanoformulated long-acting cabotegravir prodrugs are shown to be capable of extending the native drug’s antiretroviral activity, biodistribution and pharmacokinetics for up to 12 months in mice and rhesus macaques.

    • Tanmay A. Kulkarni
    • Aditya N. Bade
    • Howard E. Gendelman
    Research
    Nature Materials
    Volume: 19, P: 910-920

  • Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable apparent half-life and the potential for bimonthly drug administration.

    • Brady Sillman
    • Aditya N. Bade
    • Howard E. Gendelman
    ResearchOpen Access
    Nature Communications
    Volume: 9, P: 1-14

  • Here, the authors provide a mechanism for an improved version of a nanoformulated myristoylated prodrug of cabotegravir (CAB), named NM2CAB, and its bioavailability, stability and pharmacokinetics in mice and rats performed in independent academic and a contracted research labs, suggesting that the extended half-life of the prodrug is not a property of enzymatic hydrolysis but rather release or dissolution of the prodrug from the nanocrystal.

    • Nagsen Gautam
    • JoEllyn M. McMillan
    • Yazen Alnouti
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-13

  • Nanoparticle mimics of heparan sulfate proteoglycans offer a new strategy for the inhibition of a range of viral infections.

    • Benson J. Edagwa
    • Howard E. Gendelman
    News & Views
    Nature Materials
    Volume: 17, P: 114-116

  • Here, the authors show that sequential treatment with long-acting slow-effective release ART and AAV9- based delivery of CRISPR-Cas9 results in undetectable levels of virus and integrated DNA in a subset of humanized HIV-1 infected mice. This proof-of-concept study suggests that HIV-1 elimination is possible.

    • Prasanta K. Dash
    • Rafal Kaminski
    • Howard E. Gendelman
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-20

  • This Review highlights the progress that has been made in the development of diagnostic tools for the detection of SARS-CoV-2 in the fight against COVID-19.

    • Bhavesh D. Kevadiya
    • Jatin Machhi
    • Howard E. Gendelman
    Reviews
    Nature Materials
    Volume: 20, P: 593-605